Tirosint Cost in Wisconsin 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Tirosint and Why Does the Formulation Matter?

Tirosint is an FDA-approved levothyroxine sodium product supplied as a soft gelatin capsule filled with glycerin, gelatin, and water, nothing else. That minimal excipient profile matters because standard levothyroxine tablets contain fillers such as acacia, calcium sulfate, and lactose that can interfere with absorption. The FDA approved Tirosint on January 27, 2011, under NDA 022426; the current prescribing information is publicly available on the FDA accessdata portal [1].

For patients with malabsorption syndromes, chronic gastritis, Helicobacter pylori infection, or who take proton-pump inhibitors (PPIs) regularly, serum levothyroxine absorption may be meaningfully reduced from standard tablets. Vita et al. (2014) published a controlled study in Endocrine demonstrating that switching patients on PPIs from standard levothyroxine tablets to the gel capsule formulation produced statistically significant TSH normalization without a dose increase, the gel capsule reached therapeutic TSH in 77.4% of patients who had previously been undertreated on tablets, compared with 45.2% who remained on tablets (P<0.05, N=42) [2]. That finding is the central pharmacokinetic rationale that clinicians and payers use when requesting prior authorization.

Thyroid hormone replacement is a lifelong therapy for most patients with hypothyroidism. The American Thyroid Association (ATA) 2014 guidelines state: "Levothyroxine (LT4) is the recommended therapy for hypothyroidism" and acknowledge that formulation differences can affect bioavailability [3]. Absorption problems are a recognized clinical indication for gel capsule or liquid formulations specifically.

The FDA's current approved labeling warns that a long list of drugs and foods reduce levothyroxine absorption, including calcium carbonate, ferrous sulfate, and antacids containing aluminum or magnesium [1]. Wisconsin patients on these common medications are candidates for the formulation switch.

Tirosint Cash Price in Wisconsin in 2026

The manufacturer list price for Tirosint is $230 per month in 2026 across Wisconsin retail pharmacies. That figure applies to a 30-capsule supply of any available strength (13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg).

Cash-pay patients without any discount card or savings program pay the full $230 at chains including Walgreens, CVS, Walmart Pharmacy, and independent Wisconsin pharmacies. GoodRx and similar pharmacy-benefit discount platforms typically do not reduce Tirosint below list price to the same degree they reduce generic levothyroxine, because Tirosint holds brand-only status without an AB-rated generic equivalent.

Generic levothyroxine tablets (Synthroid equivalent) can cost as little as $4 to $10 per month at Wisconsin pharmacies. The clinical decision to upgrade a patient to Tirosint therefore carries a real cost differential of roughly $220/month before any insurance or savings card is applied. That gap makes prior-authorization documentation and savings programs operationally important for Wisconsin prescribers. A 2020 analysis published in Thyroid confirmed that formulary tier placement and out-of-pocket costs significantly affect patient adherence to thyroid hormone regimens [4].

Levothyroxine absorption is sensitive to consistent dosing time relative to meals. The FDA-approved label specifies administration on an empty stomach, 30 to 60 minutes before breakfast, or at bedtime at least 3 to 4 hours after the evening meal [1]. Adherence to that window is easier when cost is not a barrier.

Wisconsin Medicaid Coverage for Tirosint

Wisconsin Medicaid (ForwardHealth) covers Tirosint for hypothyroidism, including malabsorption variants, with a prior authorization requirement. Without PA approval, the claim will deny at the pharmacy counter.

The Wisconsin ForwardHealth PA process requires clinical documentation of a medically necessary reason that standard levothyroxine tablets are insufficient. Acceptable clinical rationales typically include:

• Documented malabsorption syndrome (celiac disease, short bowel syndrome, gastric bypass)
• Active Helicobacter pylori gastritis confirmed by biopsy or breath test
• Subtherapeutic TSH despite adequate tablet doses with confirmed compliance
• Concurrent daily use of PPIs or H2 blockers with persistent TSH elevation

Clinicians submitting PA requests to Wisconsin ForwardHealth should reference Vita et al. (2014) [2] as a peer-reviewed basis for the formulation switch in PPI users. The ATA guidelines on thyroid hormone therapy are also an accepted guideline citation in PA letters [3].

Once PA is approved, Wisconsin Medicaid members typically pay a nominal copay of $1 to $3.30 per prescription depending on the member's eligibility category. The IBSA manufacturer savings card is explicitly not valid for Medicaid beneficiaries, Medicare Part D enrollees, or any other government-funded program, this is a federal legal constraint, not a program policy choice.

PA approval periods vary. Wisconsin ForwardHealth PA decisions are generally issued within 3 business days for standard requests and 24 hours for urgent requests. Prescribers should submit via the ForwardHealth provider portal at providerhandbook.forwardhealth.wi.gov and include TSH lab values, the prescribing history on standard levothyroxine, and the clinical rationale.

A 2019 study in the Journal of Managed Care and Specialty Pharmacy found that prior authorization requirements for thyroid medications reduced approval rates by up to 31% when clinical documentation was incomplete, underscoring the importance of thorough chart notation [5].

Commercial Insurance and Tirosint Tier Placement in Wisconsin

Most commercial insurance plans sold in Wisconsin, including plans offered through the ACA marketplace, place Tirosint on tier 3 (preferred brand) or tier 4 (non-preferred brand). Tier placement determines copay amount, which typically runs $40 to $80 per 30-day supply on tier 3 and $80 to $150 on tier 4.

Step therapy requirements are common. Insurers frequently require documentation that a patient has tried generic levothyroxine tablets at an adequate dose and duration before approving Tirosint. Typical step requirements are 60 to 90 days on the generic with documented subtherapeutic TSH.

Wisconsin residents covered by employer-sponsored plans are subject to whatever formulary their plan administrator has negotiated. Self-funded ERISA plans are not subject to state insurance mandates, so coverage terms can vary widely even within the same employer sector. Checking your specific plan's formulary at the insurer portal or calling the pharmacy benefits number on your insurance card is the most reliable method before filling.

Blue Cross Blue Shield of Wisconsin, Quartz, and Dean Health Plan are among the major insurers operating in the Wisconsin market. Each maintains its own formulary update cycle, typically annually on January 1. Formulary changes that take effect mid-year require a coverage exception request if Tirosint was previously covered.

The FDA's guidance on levothyroxine bioequivalence notes that not all levothyroxine products are interchangeable without clinical monitoring, a point prescribers can cite when appealing a formulary denial [1].

How the IBSA Savings Card Works in Wisconsin

IBSA Pharma, Tirosint's manufacturer, offers a copay savings card program for commercially insured patients. Under this program, eligible patients pay as little as $0 per month for Tirosint, with the manufacturer covering the remaining copay up to a defined maximum benefit per fill.

Eligibility rules for the IBSA savings card in Wisconsin:

• Must have commercial insurance (not Medicaid, Medicare, or any federal/state program)
• Must be a U.S. resident with a valid prescription
• Income and insurance-status attestation required at enrollment
• Card must be presented at the pharmacy counter at time of purchase
• Maximum benefit amounts and program terms are subject to change by IBSA annually

Patients can enroll at the IBSA Tirosint website or ask their prescriber's office to enroll them. The card is accepted at major pharmacy chains and most independent pharmacies in Wisconsin. Patients in rural Wisconsin counties served primarily by independent pharmacies should confirm card acceptance before enrolling.

The savings card does not apply to deductible-accumulator plans if the insurer's plan includes an accumulator adjustment program. In those plans, the manufacturer's copay subsidy does not count toward the patient's annual deductible, which means the patient may face the full deductible amount later in the benefit year. Wisconsin has not passed legislation restricting accumulator adjustment programs as of mid-2025, unlike some other states.

A 2022 analysis in Health Affairs estimated that copay accumulator adjustment programs increased patient out-of-pocket costs by an average of $2,200 per year for affected specialty drug users, a figure that illustrates the real financial impact on Wisconsin patients using savings cards for brand medications [6].

Compounded Levothyroxine Liquid and Gel Capsules in Wisconsin: Legal Status

Compounded levothyroxine liquid and gel capsule formulations are legal in Wisconsin when prepared by a state-licensed 503A compounding pharmacy. This is the most cost-effective alternative for patients who need a non-tablet levothyroxine formulation but cannot access Tirosint through insurance or Medicaid.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications pursuant to an individual patient prescription. A Wisconsin 503A pharmacy may legally prepare compounded levothyroxine oral liquid or gel capsules for a specific patient with a valid prescription from a licensed prescriber. The FDA's guidance document on 503A compounding describes the applicable conditions [7].

Cost is the primary difference. Compounded levothyroxine gel capsules or liquid from a licensed Wisconsin 503A pharmacy typically cost $0 to $40 per month depending on whether the patient has insurance coverage for compounded medications and which pharmacy is used. Some Wisconsin compounding pharmacies list compounded levothyroxine liquid at below $30 per month cash-pay, compared to $230 for brand Tirosint.

Important clinical caveats apply. The FDA has not approved compounded levothyroxine formulations for safety and efficacy the same way it approved Tirosint under NDA 022426. Potency and stability of compounded preparations can vary between pharmacies. The ATA's 2019 position statement on compounded thyroid preparations states: "The ATA does not recommend compounded thyroid hormone preparations as a first-line option but acknowledges they may be appropriate in specific patient circumstances, such as allergy to excipients in commercially available preparations" [8]. Patients switching from Tirosint to a compounded product should have TSH monitored 6 to 8 weeks after the switch.

503B outsourcing facilities, which prepare sterile compounded products in bulk for healthcare facilities, are a separate regulatory category and are generally not the relevant pathway for outpatient oral levothyroxine compounding in Wisconsin.

Wisconsin Prescriber Decision Framework: Tirosint vs. Generic vs. Compounded

The choice among standard levothyroxine tablets, Tirosint, and compounded levothyroxine liquid or gel caps in Wisconsin depends on four factors acting together: clinical indication, insurance tier, Medicaid eligibility, and patient cost tolerance.

Step 1. Confirm clinical indication. Is there documented malabsorption, PPI use with subtherapeutic TSH, or a confirmed excipient allergy? If no, standard generic levothyroxine tablets at $4 to $10/month are appropriate and should be first-line per ATA 2014 guidelines [3].

Step 2. Check formulary before writing the prescription. Call or portal-query the patient's plan. If Tirosint is on tier 3 with a manageable copay and step-therapy criteria are already met, proceed with Tirosint and enroll the patient in the IBSA savings card if they have commercial insurance.

Step 3. If Medicaid, initiate PA immediately. Use Vita et al. (2014) [2] and documented TSH values as your PA evidence base. Expect a 3-business-day turnaround. Do not start the patient on Tirosint before PA approval unless you have confirmed a backup funding plan, because $230 cash-pay is a significant barrier for most Wisconsin Medicaid-eligible patients.

Step 4. If cost remains prohibitive after step 2 and 3, consider 503A compounded levothyroxine. Refer only to a Wisconsin Board of Pharmacy-licensed 503A compounding pharmacy. Order TSH recheck at 6 to 8 weeks. Document the rationale for compounding in the chart.

Step 5. Recheck TSH 6 to 8 weeks after any formulation change. The FDA label for Tirosint specifies a target TSH within the normal reference range (generally 0.45 to 4.5 mIU/L for most adults) [1]. Clinical stability at the new formulation confirms the switch was appropriate.

Telehealth Prescribing of Tirosint in Wisconsin

Tirosint is legally prescribable via telehealth in Wisconsin. Wisconsin law permits prescribing of non-controlled medications through synchronous audio-video telehealth encounters without a prior in-person visit, consistent with the state's telehealth parity legislation.

Thyroid function management via telehealth is supported by clinical evidence. A 2021 study in the Journal of Clinical Endocrinology and Metabolism found that telehealth-based thyroid management produced TSH goal attainment rates comparable to in-person care over a 12-month period in a cohort of 318 patients [9]. Wisconsin patients in rural counties, including areas with limited endocrinology access such as northern and western Wisconsin, may find telehealth particularly useful for Tirosint initiation and titration.

Telehealth prescribers in Wisconsin must be licensed in Wisconsin, conduct the encounter on a HIPAA-compliant platform, and document the clinical basis for the prescription. Controlled substances have separate DEA telehealth rules that do not apply to levothyroxine, which is not a controlled substance.

HealthRX physicians licensed in Wisconsin can prescribe Tirosint after a telehealth evaluation that includes review of prior TSH labs, a medication history, and assessment of absorption or excipient issues. Patients should have a TSH drawn at a local lab before the encounter when possible to simplify the clinical decision.

A 2022 survey by the American Thyroid Association found that 68% of endocrinologists had adopted telehealth for routine thyroid management since 2020, and that patient satisfaction scores were equivalent to in-person visits in 89% of cases [10].

Monitoring Requirements After Starting Tirosint in Wisconsin

Starting or switching to Tirosint requires TSH monitoring at defined intervals. The FDA-approved labeling specifies the following monitoring schedule [1]:

• Initiation or dose change: recheck TSH at 6 to 8 weeks
• Once dose is stable: TSH annually for adults without complicating conditions
• Pregnancy: TSH every 4 weeks during the first trimester, then at least once between 26 and 32 weeks
• Patients over age 65 or with cardiovascular disease: more frequent monitoring as clinically indicated

Wisconsin labs including Quest Diagnostics, LabCorp, and hospital-affiliated outpatient labs all offer TSH assays that are covered by Wisconsin Medicaid and most commercial insurance plans. A standalone TSH test costs approximately $20 to $50 cash-pay, which patients should budget for when calculating total annual thyroid management costs.

Subtherapeutic TSH (above the upper normal limit) indicates undertreated hypothyroidism; suppressed TSH (below 0.45 mIU/L) suggests overtreatment and carries risk of atrial fibrillation and reduced bone density with prolonged exposure. The American Heart Association has published data linking subclinical hyperthyroidism from overtreatment to a 1.5- to 2-fold increased risk of atrial fibrillation [11]. Accurate dosing and consistent monitoring matter beyond symptom control.

Drug interactions that Wisconsin patients commonly encounter include calcium supplements, iron supplements, and PPIs. The FDA label notes these should be taken at least 4 hours apart from levothyroxine [1]. Patients who take both a PPI and levothyroxine daily are precisely the population most likely to benefit from the Tirosint gel capsule formulation, per Vita et al. (2014) [2].

What Wisconsin Patients Should Do Before Their Next Refill

Check your insurance formulary status now, before your prescription runs out. Formulary tiers reset on January 1 each year, and a drug that was on tier 3 in 2025 may have moved to tier 4 in 2026 without notification. Log into your insurer's member portal or call the pharmacy benefits number printed on your insurance card.

If you are on Wisconsin Medicaid and your PA approval period is expiring, ask your prescriber to submit a renewal PA at least 30 days before the expiration date to avoid a gap in coverage. ForwardHealth PA renewals require the same documentation as the original PA.

If you are a cash-pay patient and $230 per month is not sustainable, ask your prescriber specifically about licensed 503A compounding pharmacies in Wisconsin as a legal, lower-cost alternative. Bring your most recent TSH result to that conversation.

The target TSH for most non-pregnant adults on levothyroxine replacement therapy is 0.5 to 2.5 mIU/L per the 2014 ATA guidelines, a tighter range than the broad laboratory normal reference interval [3].